Free Trial

Organon & Co. (OGN) Competitors

Organon & Co. logo
$14.52 -0.05 (-0.31%)
Closing price 03/28/2025 03:59 PM Eastern
Extended Trading
$14.57 +0.05 (+0.38%)
As of 03/28/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OGN vs. SMMT, ITCI, MRNA, GMAB, RDY, VTRS, ASND, PCVX, QGEN, and ROIV

Should you be buying Organon & Co. stock or one of its competitors? The main competitors of Organon & Co. include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Moderna (MRNA), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Ascendis Pharma A/S (ASND), Vaxcyte (PCVX), Qiagen (QGEN), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.

Organon & Co. vs.

Organon & Co. (NYSE:OGN) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 1.4% of Organon & Co. shares are owned by company insiders. Comparatively, 88.3% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Organon & Co. has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.04, indicating that its stock price is 204% less volatile than the S&P 500.

Summit Therapeutics received 290 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 58.56% of users gave Summit Therapeutics an outperform vote while only 33.96% of users gave Organon & Co. an outperform vote.

CompanyUnderperformOutperform
Organon & Co.Outperform Votes
18
33.96%
Underperform Votes
35
66.04%
Summit TherapeuticsOutperform Votes
308
58.56%
Underperform Votes
218
41.44%

In the previous week, Summit Therapeutics had 5 more articles in the media than Organon & Co.. MarketBeat recorded 16 mentions for Summit Therapeutics and 11 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.40 beat Summit Therapeutics' score of 0.70 indicating that Organon & Co. is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Organon & Co.
9 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Summit Therapeutics
7 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Organon & Co. currently has a consensus target price of $20.80, suggesting a potential upside of 43.30%. Summit Therapeutics has a consensus target price of $35.44, suggesting a potential upside of 74.43%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Organon & Co..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organon & Co.
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.43
Summit Therapeutics
0 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
3.00

Organon & Co. has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organon & Co.$6.40B0.58$864M$3.334.36
Summit Therapeutics$700K21,413.80-$614.93M-$0.31-65.55

Organon & Co. has a net margin of 13.49% compared to Summit Therapeutics' net margin of 0.00%. Organon & Co.'s return on equity of 431.62% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Organon & Co.13.49% 431.62% 8.03%
Summit Therapeutics N/A -85.42%-52.66%

Summary

Organon & Co. beats Summit Therapeutics on 11 of the 19 factors compared between the two stocks.

Remove Ads
Get Organon & Co. News Delivered to You Automatically

Sign up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OGN vs. The Competition

MetricOrganon & Co.Pharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$3.74B$6.90B$5.63B$19.40B
Dividend Yield7.28%2.75%5.33%3.75%
P/E Ratio4.367.2623.5333.04
Price / Sales0.58218.61388.1926.59
Price / Cash3.1265.6738.1717.55
Price / Book-53.766.386.894.53
Net Income$864M$142.34M$3.20B$1.02B
7 Day Performance-5.32%-5.15%-3.06%-1.30%
1 Month Performance-2.62%-7.55%1.51%-4.04%
1 Year Performance-22.79%-11.06%9.35%2.59%

Organon & Co. Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OGN
Organon & Co.
4.7547 of 5 stars
$14.52
-0.3%
$20.80
+43.3%
-22.8%$3.74B$6.40B4.3610,000News Coverage
Positive News
SMMT
Summit Therapeutics
2.8186 of 5 stars
$20.69
+4.8%
$34.11
+64.9%
+390.8%$15.26B$700,000.00-73.89110Analyst Upgrade
News Coverage
ITCI
Intra-Cellular Therapies
3.584 of 5 stars
$131.70
+0.0%
$106.08
-19.5%
+90.5%$14.00B$680.50M-151.38560Analyst Forecast
News Coverage
Positive News
MRNA
Moderna
4.0977 of 5 stars
$34.17
+4.6%
$59.00
+72.7%
-70.8%$13.18B$3.20B-3.683,900
GMAB
Genmab A/S
3.9 of 5 stars
$19.29
-2.4%
$41.33
+114.3%
-33.5%$12.77B$21.53B11.092,204Short Interest ↑
News Coverage
Gap Down
RDY
Dr. Reddy's Laboratories
3.3939 of 5 stars
$13.72
+0.0%
$17.00
+24.0%
-10.1%$11.45B$311.31B21.8424,800Positive News
High Trading Volume
VTRS
Viatris
1.8703 of 5 stars
$9.30
+1.6%
$10.50
+12.9%
-27.3%$11.10B$14.74B-12.5737,000Short Interest ↑
ASND
Ascendis Pharma A/S
3.1232 of 5 stars
$167.99
+1.2%
$204.64
+21.8%
+2.3%$10.20B$363.64M-23.661,017News Coverage
Positive News
PCVX
Vaxcyte
2.0634 of 5 stars
$73.82
-1.1%
$147.50
+99.8%
+1.7%$9.51BN/A-16.05160News Coverage
Positive News
QGEN
Qiagen
3.4085 of 5 stars
$39.87
+0.5%
$47.71
+19.7%
-4.6%$8.85B$1.98B111.026,030Short Interest ↑
News Coverage
ROIV
Roivant Sciences
2.3706 of 5 stars
$10.83
+0.4%
$18.08
+67.0%
-1.5%$7.73B$122.59M-72.20860Positive News
Remove Ads

Related Companies and Tools


This page (NYSE:OGN) was last updated on 3/30/2025 by MarketBeat.com Staff
From Our Partners